Low expression of microRNA-129-5p predicts poor clinical outcome in diffuse large B cell lymphoma (DLBCL)

International Journal of Hematology

Volumn 97, Issue 4, 2013, Pages 465-471

  Hedström, Gustav ^a   Thunberg, Ulf ^a   Berglund, Mattias ^a   Simonsson, Martin ^a   Amini, Rose Marie ^a   Enblad, Gunilla ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

DLBCL; Microrna 129 5p; Prognosis

Indexed keywords

CYCLIN DEPENDENT KINASE 6; CYCLOPHOSPHAMIDE; DOXORUBICIN; MICRORNA; MICRORNA 129 5P; PREDNISONE; RITUXIMAB; TRANSCRIPTION FACTOR SOX4; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; MIRN129 MICRORNA, HUMAN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER TISSUE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; ADOLESCENT; CANCER STAGING; GENE EXPRESSION REGULATION; GENETICS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MORTALITY; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; YOUNG ADULT;

EID: 84891691150     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-013-1303-2     Document Type: Article

References (35)

1. Habermann TM, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121-7.
2. Rosenwald A, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New Engl J Med. 2002;346(25):1937-47.
3. Alizadeh AA, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-11.
4. Ninan MJ, Wadhwa PD, Gupta P. Prognostication of diffuse large B-cell lymphoma in the rituximab era. Leuk lymphoma. 2011; 52(3):360-73.
5. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol. 2009;10(2):126-39.
6. Valencia-Sanchez MA, et al. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006;20(5): 515-24.
7. Davis-Dusenbery BN, Hata A. MicroRNA in cancer: the involvement of aberrant microrna biogenesis regulatory pathways. Genes Cancer. 2010;1(11):1100-14.
8. Hobert O. Common logic of transcription factor and microRNA action. Trends Biochem Sci. 2004;29(9):462-8.
9. Alencar AJ, et al. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res. 2011;17(12):4125-35.
10. Calin GA, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. New Engl J Med. 2005;353(17):1793-801.
11. Marcucci G, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. New Engl J Med. 2008; 358(18):1919-28.
12. Montes-Moreno S, et al. miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Blood. 2011;118(4):1034-40.
13. Schwind S, et al. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2010;28(36):5257-64.
14. Yanaihara N, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9(3):189-98.
15. Liao R, et al. MicroRNAs play a role in the development of human hematopoietic stem cells. J Cell Biochem. 2008; 104(3):805-17.
16. Wu J, et al. miR-129 regulates cell proliferation by downregulating Cdk6 expression. Cell Cycle. 2010;9(9):1809-18.
17. Huang YW, et al. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res. 2009;69(23):9038-46.
18. Nicoloso MS, et al. MicroRNAs-the micro steering wheel of tumour metastases. Nat Rev Cancer. 2009;9(4):293-302.
19. Shen R, et al. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 in gastric cancer. Biochem Biophys Res Commun. 2010;394(4):1047-52.
20. Tsai KW, et al. Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. Int J Cancer. 2011;129(11):2600-10.
21. Dyrskjot L, et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res. 2009;69(11):4851-60.
22. Hans CP, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-82.
23. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29(9):e45.
24. Lawrie CH, et al. Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med. 2009;13(7):1248-60.
25. Castillo JJ, et al. The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res. 2012;36(4):413-7.
26. Choi WW, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15(17):5494-502.
27. Meyer SU, et al. Profound effect of profiling platform and normalization strategy on detection of differentially expressed microRNAs- a comparative study. PLoS ONE. 2012;7(6):e38946.
28. Katada T, et al. microRNA expression profile in undifferentiated gastric cancer. Int J Oncol. 2009;34(2):537-42.
29. Tavazoie SF, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451(7175):147-52.
30. Menon MP, Pittaluga S, Jaffe ES. The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification. Cancer J. 2012;18(5):411-20.
31. Swerdlow SH, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. In: WHO classification of tumours, vol. 22008, 4th ed. Lyon: WHO; 2008. p. 439.
32. Castillo JJ, et al. Epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far. Oncologist. 2011;16(1):87-96.
33. Hoeller S, et al. Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. Hum Pathol. 2010;41(3):352-7.
34. Kim JH, Kim WS, Park C. Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1. Leuk Lymphoma. 2012;53(8):1586-91.
35. Rosato P, et al. Differential regulation of miR-21 and miR-146a by Epstein-Barr virus-encoded EBNA2. Leukemia. 2012;26(11): 2343-52.